Dirk Spitzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dirk Spitzer has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Brian Andrew Van Tine
Washington University in St. Louis
20 shared publications - William G. Hawkins
Medical University of South Carolina 1 Charleston, SC
19 shared publications - Caitlyn B. Brashears
Washington University in St. Louis 2 Saint Louis, MO
14 shared publications - Katharine E. Caldwell
Department of Surgery, Division of Surgical Oncology, Medical University of South Carolina, Charleston, USA
14 shared publications - Bethany C. Prudner
Division of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri
13 shared publications Carina A. Dehner
13 shared publications
Latest Publications
- 22 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Differential Sensitivity to xCT-inhibition by ME1 expression
Many cancers overexpress malic enzyme 1 (ME1), an enzyme essential in redox homeostasis through the generation of cytoplasmic NADPH. While ME1 overexpression is correlated with aggressive cancer phenotypes, little is known about the metabolic consequences of ME1 absence, recently identified as characteristic of synovial sarcoma. ACXT-3102 is a novel, dual-domain therapeutic produced by the conjugation of erastin, a small molecule xCT-inhibitor, and sigma-2 ligand, shown to induce ROS-dependent cell death in various cancer models. This study examines ME1 absence as a marker of sensitivity to xCT-inhibition in multiple malignancies and its role as a potential therapeutic marker for ACXT-3102 treatment. ME1-expressing and non-expressing tumor cell lines were identified and matched ME1 knockdown (KD) and overexpressing (OE) lines were created. Sensitivity to ACXT-3102 treatment was investigated in various tumor lines in vitro and in vivo. ME1 absence is identified in a subset of multiple malignancies. ME1 KD increases ME1-expressing tumor cell sensitivity to ACXT-3102, while ME1 re-introduction decreases xCT-inhibition sensitivity in ME1-null lines in in vitro and in vivo models. Compared to ME1-expressing cancers, ME1 absence increases tumor sensitivity to xCT inhibition. Our findings suggest ME1-null and low-expressing tumors constitute a distinct subset across multiple solid tumor types, representing a potential metabolic vulnerability. Given this differential sensitivity, ME1 deficiency may serve as a promising biomarker for selecting patients likely to benefit from xCT-targeting therapies. These results support further investigation into ME1 expression as a predictive tool for clinical trial stratification and of xCT-inhibition treatment strategies.
- 22 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Differential Sensitivity to xCT-inhibition by ME1 expression
Many cancers overexpress malic enzyme 1 (ME1), an enzyme essential in redox homeostasis through the generation of cytoplasmic NADPH. While ME1 overexpression is correlated with aggressive cancer phenotypes, little is known about the metabolic consequences of ME1 absence, recently identified as characteristic of synovial sarcoma. ACXT-3102 is a novel, dual-domain therapeutic produced by the conjugation of erastin, a small molecule xCT-inhibitor, and sigma-2 ligand, shown to induce ROS-dependent cell death in various cancer models. This study examines ME1 absence as a marker of sensitivity to xCT-inhibition in multiple malignancies and its role as a potential therapeutic marker for ACXT-3102 treatment. ME1-expressing and non-expressing tumor cell lines were identified and matched ME1 knockdown (KD) and overexpressing (OE) lines were created. Sensitivity to ACXT-3102 treatment was investigated in various tumor lines in vitro and in vivo. ME1 absence is identified in a subset of multiple malignancies. ME1 KD increases ME1-expressing tumor cell sensitivity to ACXT-3102, while ME1 re-introduction decreases xCT-inhibition sensitivity in ME1-null lines in in vitro and in vivo models. Compared to ME1-expressing cancers, ME1 absence increases tumor sensitivity to xCT inhibition. Our findings suggest ME1-null and low-expressing tumors constitute a distinct subset across multiple solid tumor types, representing a potential metabolic vulnerability. Given this differential sensitivity, ME1 deficiency may serve as a promising biomarker for selecting patients likely to benefit from xCT-targeting therapies. These results support further investigation into ME1 expression as a predictive tool for clinical trial stratification and of xCT-inhibition treatment strategies.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Ferroptosis has recently been described as an iron-dependent subroutine of programmed cell death. Cancers driven by oncogenic Ras mutations, such as pancreatic ductal adenocarcinoma, are particularly vulnerable to ferroptosis and are thus promising candidates for antineoplastic drugs targeting this unique form of programmed cell death. Our group has developed a cancer-specific drug conjugate (ACXT-3102), consisting of a proapoptotic sigma-2 ligand as a delivery moiety (SV119), linked to an inhibitor of the cystine antiporter xCT (dm-erastin), an established inducer of ferroptosis. We hypothesized that ACXT-3102 would trigger apoptosis and ferroptosis via its discrete chemical components, representing a new approach to clinical therapy for pancreatic ductal adenocarcinoma. In vitro cell viability assays corroborated our earlier findings that ACXT-3102 is a potent inducer of cancer cell death. The sigma-2 delivery component of ACXT-3102 induced canonical markers of apoptosis, including cleaved caspase-3/7 and PARP, whereas the dm-erastin cargo component induced canonical markers of ferroptosis, including lipid peroxidation and consumption of glutathione peroxidase 4. These changes resulted in the accumulation of reactive oxygen species. Subsequently, we found that ACXT-3102–mediated cell death was accompanied by the activation of MAPK/ERK signaling, presumably via the reactive oxygen species–dependent degradation of dual-specificity phosphatase 6, a negative regulator of MAPK/ERK phosphorylation. We suspected that this was a compensatory reaction and that ACXT-3102–induced cancer cell death would be augmented by inhibition of MAPK/ERK signaling. We successfully combined ACXT-3102 with trametinib (MEK inhibitor) to enhance the overall efficacy of treatment in vitro and in vivo, presumably by targeting ACXT-3102–induced upregulation of MAPK/ERK.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Ferroptosis has recently been described as an iron-dependent subroutine of programmed cell death. Cancers driven by oncogenic Ras mutations, such as pancreatic ductal adenocarcinoma, are particularly vulnerable to ferroptosis and are thus promising candidates for antineoplastic drugs targeting this unique form of programmed cell death. Our group has developed a cancer-specific drug conjugate (ACXT-3102), consisting of a proapoptotic sigma-2 ligand as a delivery moiety (SV119), linked to an inhibitor of the cystine antiporter xCT (dm-erastin), an established inducer of ferroptosis. We hypothesized that ACXT-3102 would trigger apoptosis and ferroptosis via its discrete chemical components, representing a new approach to clinical therapy for pancreatic ductal adenocarcinoma. In vitro cell viability assays corroborated our earlier findings that ACXT-3102 is a potent inducer of cancer cell death. The sigma-2 delivery component of ACXT-3102 induced canonical markers of apoptosis, including cleaved caspase-3/7 and PARP, whereas the dm-erastin cargo component induced canonical markers of ferroptosis, including lipid peroxidation and consumption of glutathione peroxidase 4. These changes resulted in the accumulation of reactive oxygen species. Subsequently, we found that ACXT-3102–mediated cell death was accompanied by the activation of MAPK/ERK signaling, presumably via the reactive oxygen species–dependent degradation of dual-specificity phosphatase 6, a negative regulator of MAPK/ERK phosphorylation. We suspected that this was a compensatory reaction and that ACXT-3102–induced cancer cell death would be augmented by inhibition of MAPK/ERK signaling. We successfully combined ACXT-3102 with trametinib (MEK inhibitor) to enhance the overall efficacy of treatment in vitro and in vivo, presumably by targeting ACXT-3102–induced upregulation of MAPK/ERK.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
RNAseq analysis demonstrates ACXT-3102-mediated decrease in DUSP6 expression in human synovial sarcoma cells (SYO1).
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
RNAseq analysis demonstrates ACXT-3102-mediated decrease in DUSP6 expression in human synovial sarcoma cells (SYO1).
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Cell viability assays exhibiting ferrostatin-1 and deferoxamine (ferroptosis-specific inhibitors)-mediated blocking of ACXT-3102-induced cell death in PDAC (BxPC-3, AsPC-1, and PANC-1) cells.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Cell viability assays exhibiting ferrostatin-1 and deferoxamine (ferroptosis-specific inhibitors)-mediated blocking of ACXT-3102-induced cell death in PDAC (BxPC-3, AsPC-1, and PANC-1) cells.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Trametinib potentiates ACXT-3102 cytotoxicity in vitro.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Trametinib potentiates ACXT-3102 cytotoxicity in vitro.
- 3 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (12) , 1902-1913
Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Ferroptosis has recently been described as an iron-dependent subroutine of programmed cell death. Cancers driven by oncogenic Ras mutations, such as pancreatic ductal adenocarcinoma, are particularly vulnerable to ferroptosis and are thus promising candidates for antineoplastic drugs targeting this unique form of programmed cell death. Our group has developed a cancer-specific drug conjugate (ACXT-3102), consisting of a proapoptotic sigma-2 ligand as a delivery moiety (SV119), linked to an inhibitor of the cystine antiporter xCT (dm-erastin), an established inducer of ferroptosis. We hypothesized that ACXT-3102 would trigger apoptosis and ferroptosis via its discrete chemical components, representing a new approach to clinical therapy for pancreatic ductal adenocarcinoma. In vitro cell viability assays corroborated our earlier findings that ACXT-3102 is a potent inducer of cancer cell death. The sigma-2 delivery component of ACXT-3102 induced canonical markers of apoptosis, including cleaved caspase-3/7 and PARP, whereas the dm-erastin cargo component induced canonical markers of ferroptosis, including lipid peroxidation and consumption of glutathione peroxidase 4. These changes resulted in the accumulation of reactive oxygen species. Subsequently, we found that ACXT-3102–mediated cell death was accompanied by the activation of MAPK/ERK signaling, presumably via the reactive oxygen species–dependent degradation of dual-specificity phosphatase 6, a negative regulator of MAPK/ERK phosphorylation. We suspected that this was a compensatory reaction and that ACXT-3102–induced cancer cell death would be augmented by inhibition of MAPK/ERK signaling. We successfully combined ACXT-3102 with trametinib (MEK inhibitor) to enhance the overall efficacy of treatment in vitro and in vivo, presumably by targeting ACXT-3102–induced upregulation of MAPK/ERK.
- 3 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (12) , 1902-1913
Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death
Ferroptosis has recently been described as an iron-dependent subroutine of programmed cell death. Cancers driven by oncogenic Ras mutations, such as pancreatic ductal adenocarcinoma, are particularly vulnerable to ferroptosis and are thus promising candidates for antineoplastic drugs targeting this unique form of programmed cell death. Our group has developed a cancer-specific drug conjugate (ACXT-3102), consisting of a proapoptotic sigma-2 ligand as a delivery moiety (SV119), linked to an inhibitor of the cystine antiporter xCT (dm-erastin), an established inducer of ferroptosis. We hypothesized that ACXT-3102 would trigger apoptosis and ferroptosis via its discrete chemical components, representing a new approach to clinical therapy for pancreatic ductal adenocarcinoma. In vitro cell viability assays corroborated our earlier findings that ACXT-3102 is a potent inducer of cancer cell death. The sigma-2 delivery component of ACXT-3102 induced canonical markers of apoptosis, including cleaved caspase-3/7 and PARP, whereas the dm-erastin cargo component induced canonical markers of ferroptosis, including lipid peroxidation and consumption of glutathione peroxidase 4. These changes resulted in the accumulation of reactive oxygen species. Subsequently, we found that ACXT-3102–mediated cell death was accompanied by the activation of MAPK/ERK signaling, presumably via the reactive oxygen species–dependent degradation of dual-specificity phosphatase 6, a negative regulator of MAPK/ERK phosphorylation. We suspected that this was a compensatory reaction and that ACXT-3102–induced cancer cell death would be augmented by inhibition of MAPK/ERK signaling. We successfully combined ACXT-3102 with trametinib (MEK inhibitor) to enhance the overall efficacy of treatment in vitro and in vivo, presumably by targeting ACXT-3102–induced upregulation of MAPK/ERK.
- Open Access
- 2 May 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (5) , 1-14
Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress
Sigma-2-ligands (S2L) are characterized by high binding affinities to their cognate sigma-2 receptor, overexpressed in rapidly proliferating tumor cells. As such, S2L were developed as imaging probes (ISO1) or as cancer therapeutics, alone (SV119 [C6], SW43 [C10]) and as delivery vehicles for cytotoxic drug cargoes (C6-Erastin, C10-SMAC). However, the exact mechanism of S2L-induced cytotoxicity remains to be fully elucidated. A series of high-affinity S2L were evaluated regarding their cytotoxicity profiles across cancer cell lines. While C6 and C10 displayed distinct cytotoxicities, C0 and ISO1 were essentially non-toxic. Confocal microscopy and lipidomics analysis in cellular and mouse models revealed that C10 induced increases in intralysosomal free cholesterol and in cholesterol esters, suggestive of unaltered intracellular cholesterol trafficking. Cytotoxicity was caused by cholesterol excess, a phenomenon that contrasts the effects of NPC1 inhibition. RNA-sequencing revealed gene clusters involved in cholesterol homeostasis and ER stress response exclusively by cytotoxic S2L. ER stress markers were confirmed by qPCR and their targeted modulation inhibited or enhanced cytotoxicity of C10 in a predicted manner. Moreover, C10 increased sterol regulatory element-binding protein 2 (SREBP2) and low-density lipoprotein receptor (LDLR), both found to be pro-survival factors activated by ER stress. Furthermore, inhibition of downstream processes of the adaptive response to S2L with simvastatin resulted in synergistic treatment outcomes in combination with C10. Of note, the S2L conjugates retained the ER stress response of the parental ligands, indicative of cholesterol homeostasis being involved in the overall cytotoxicity of the drug conjugates. Based on these findings, we conclude that S2L-mediated cell death is due to free cholesterol accumulation that leads to ER stress. Consequently, the cytotoxic profiles of S2L drug conjugates are proposed to be enhanced via concurrent ER stress inducers or simvastatin, strategies that could be instrumental on the path toward tumor eradication.
- 2 May 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (5) , 1-14
Open AccessCytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress
Sigma-2-ligands (S2L) are characterized by high binding affinities to their cognate sigma-2 receptor, overexpressed in rapidly proliferating tumor cells. As such, S2L were developed as imaging probes (ISO1) or as cancer therapeutics, alone (SV119 [C6], SW43 [C10]) and as delivery vehicles for cytotoxic drug cargoes (C6-Erastin, C10-SMAC). However, the exact mechanism of S2L-induced cytotoxicity remains to be fully elucidated. A series of high-affinity S2L were evaluated regarding their cytotoxicity profiles across cancer cell lines. While C6 and C10 displayed distinct cytotoxicities, C0 and ISO1 were essentially non-toxic. Confocal microscopy and lipidomics analysis in cellular and mouse models revealed that C10 induced increases in intralysosomal free cholesterol and in cholesterol esters, suggestive of unaltered intracellular cholesterol trafficking. Cytotoxicity was caused by cholesterol excess, a phenomenon that contrasts the effects of NPC1 inhibition. RNA-sequencing revealed gene clusters involved in cholesterol homeostasis and ER stress response exclusively by cytotoxic S2L. ER stress markers were confirmed by qPCR and their targeted modulation inhibited or enhanced cytotoxicity of C10 in a predicted manner. Moreover, C10 increased sterol regulatory element-binding protein 2 (SREBP2) and low-density lipoprotein receptor (LDLR), both found to be pro-survival factors activated by ER stress. Furthermore, inhibition of downstream processes of the adaptive response to S2L with simvastatin resulted in synergistic treatment outcomes in combination with C10. Of note, the S2L conjugates retained the ER stress response of the parental ligands, indicative of cholesterol homeostasis being involved in the overall cytotoxicity of the drug conjugates. Based on these findings, we conclude that S2L-mediated cell death is due to free cholesterol accumulation that leads to ER stress. Consequently, the cytotoxic profiles of S2L drug conjugates are proposed to be enhanced via concurrent ER stress inducers or simvastatin, strategies that could be instrumental on the path toward tumor eradication.
- Open Access
- 16 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer
Cancer selective apoptosis remains a therapeutic challenge and off-target toxicity has limited enthusiasm for this target clinically. Sigma-2 ligands (S2) have been shown to enhance the cancer selectivity of small molecule drug candidates by improving internalization. Here, we report the synthesis of a novel drug conjugate, which was created by linking a clinically underperforming SMAC mimetic (second mitochondria-derived activator of caspases; LCL161), an inhibitor (antagonist) of inhibitor of apoptosis proteins (IAPinh) with the sigma-2 ligand SW43, resulting in the new chemical entity S2/IAPinh. Drug potency was assessed via cell viability assays across several pancreatic and ovarian cancer cell lines in comparison with the individual components (S2 and IAPinh) as well as their equimolar mixtures (S2 + IAPinh) both in vitro and in preclinical models of pancreatic and ovarian cancer. Mechanistic studies of S2/IAPinh-mediated cell death were investigated in vitro and in vivo using syngeneic and xenograft mouse models of murine pancreatic and human ovarian cancer, respectively. S2/IAPinh demonstrated markedly improved pharmacological activity in cancer cell lines and primary organoid cultures when compared to the controls. In vivo testing demonstrated a marked reduction in tumor growth rates and increased survival rates when compared to the respective control groups. The predicted mechanism of action of S2/IAPinh was confirmed through assessment of apoptosis pathways and demonstrated strong target degradation (cellular inhibitor of apoptosis proteins-1 [cIAP-1]) and activation of caspases 3 and 8. Taken together, S2/IAPinh demonstrated efficacy in models of pancreatic and ovarian cancer, two challenging malignancies in need of novel treatment concepts. Our data support an in-depth investigation into utilizing S2/IAPinh for the treatment of cancer.
- 16 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessThe novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer
Cancer selective apoptosis remains a therapeutic challenge and off-target toxicity has limited enthusiasm for this target clinically. Sigma-2 ligands (S2) have been shown to enhance the cancer selectivity of small molecule drug candidates by improving internalization. Here, we report the synthesis of a novel drug conjugate, which was created by linking a clinically underperforming SMAC mimetic (second mitochondria-derived activator of caspases; LCL161), an inhibitor (antagonist) of inhibitor of apoptosis proteins (IAPinh) with the sigma-2 ligand SW43, resulting in the new chemical entity S2/IAPinh. Drug potency was assessed via cell viability assays across several pancreatic and ovarian cancer cell lines in comparison with the individual components (S2 and IAPinh) as well as their equimolar mixtures (S2 + IAPinh) both in vitro and in preclinical models of pancreatic and ovarian cancer. Mechanistic studies of S2/IAPinh-mediated cell death were investigated in vitro and in vivo using syngeneic and xenograft mouse models of murine pancreatic and human ovarian cancer, respectively. S2/IAPinh demonstrated markedly improved pharmacological activity in cancer cell lines and primary organoid cultures when compared to the controls. In vivo testing demonstrated a marked reduction in tumor growth rates and increased survival rates when compared to the respective control groups. The predicted mechanism of action of S2/IAPinh was confirmed through assessment of apoptosis pathways and demonstrated strong target degradation (cellular inhibitor of apoptosis proteins-1 [cIAP-1]) and activation of caspases 3 and 8. Taken together, S2/IAPinh demonstrated efficacy in models of pancreatic and ovarian cancer, two challenging malignancies in need of novel treatment concepts. Our data support an in-depth investigation into utilizing S2/IAPinh for the treatment of cancer.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Supplementary Data from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Supplementary Data from Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102